Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DSB2455 |
| Synonyms | |
| Therapy Description |
DSB2455 selectively inhibits PARP1, which potentially induces tumor cell cytotoxicity and antitumor activity (Eur J Cancer 211 (2024): 114858). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DSB2455 | DSB-2455|DSB 2455 | PARP-1 Inhibitor 13 | DSB2455 selectively inhibits PARP1, which potentially induces tumor cell cytotoxicity and antitumor activity (Eur J Cancer 211 (2024): 114858). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06458712 | Phase I | DSB2455 | Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies | Recruiting | USA | FRA | ESP | 0 |